A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial to study the safety and efficacy of IMMU-130. IMMU-130 is composed
of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a
common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by
the immune system. They bind to substances that don't belong in the body to prevent harm to
the body. The antibody in this study was designed to bind to a marker located on colorectal
cancer tumors. The antibody was originally made from mouse proteins, but was changed in the
laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts
for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is
safe and effective.